Shanmugam Muthusamy's Form 4/A amendment
AmendedAni Pharmaceuticals Inc (ANIP) · filed Jun 23, 2023
- Accession no.
- 0001104659-23-074399
- Filed
- Jun 23, 2023
- Trade date
- Jun 20-23, 2023
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Jun 22, 2023
This filing lists 4 non-derivative transactions. Open-market sales total $2.58M. It was filed 3 days after the trade.
This amendment replaces 0001104659-23-073894 (filed Jun 22, 2023).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shanmugam MuthusamyCIK 0001870913 | Director, Officer (HEAD OF R&D, COO-NOVITIUM OPS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 20, 2023 | Common Stock | SSaleDisposed | −14,657 | $51.93F2 | −$761,138.01 | 1,317,963 | Indirect | |
| Jun 21, 2023 | Common Stock | SSaleDisposed | −11,843 | $51.95F4 | −$615,243.85 | 1,306,120 | Indirect | |
| Jun 22, 2023 | Common Stock | SSaleDisposed | −13,500 | $51.38F5 | −$693,630 | 1,292,620 | Indirect | |
| Jun 23, 2023 | Common Stock | SSaleDisposed | −10,000 | $51.49F6 | −$514,900 | 1,282,620 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $50.63 to $52.80, inclusive. The reporting person undertakes to provide to ANIPharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4, 5 and 6 to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The reporting person holds voting and dispositive power over the shares held by Esjay LLC.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $51.13 to $52.56, inclusive.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $50.85 to $51.84, inclusive.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $50.99 to $52.08, inclusive.
Referenced by the price of 1 transaction in Table I.
- F7
The reporting person holds voting and dispositive power over the shares held by SS Pharma LLC.
Remarks
This Form 4, as originally filed, incorrectly reported the sales on June 20, 2023, June 21, 2023 and June 22, 2023 as shares held by the reporting person directly. The shares from such sales were held indirectly by the reporting person by Esjay LLC.